Articles tagged with Antidiabetics
Researchers will investigate alternative binding sites for existing diabetes medications, aiming to design more effective and safer treatments. The new grant will aid in the development of better drug models to improve glucose uptake by cells.
Scientists at Scripps Research Institute have discovered a new binding site on peroxisome proliferator-activated receptor-gamma (PPARG) that could lead to improved insulin-sensitizing drugs. This alternative site may provide clues to the adverse effects of existing anti-diabetic medications, such as bone loss and congestive heart failure.
Research published in Diabetologia suggests Sweden may have 2-3 times more adolescents and young adults with type 1 diabetes than estimated. The study used a new method to estimate incidence rates among young people, finding a significant disparity between previous estimates.
Gastric bypass and sleeve gastrectomy surgeries show significant improvement in glycemic control, weight loss, and cardiovascular risk factors compared to intensive medical therapy. Patients undergoing surgery also experience reduced reliance on medications and improved quality of life measures.
Heart failure is commonly assessed as a complication of diabetes but rarely considered as an outcome in glucose-lowering drug trials. Recent studies suggest some drugs may increase cardiovascular risk despite lowering blood glucose, prompting new regulations for cardiovascular outcomes trials.
Researchers developed a novel DiaRem score to predict likelihood of diabetes remission after gastric bypass surgery. The score considers four factors: insulin use, age, haemoglobin A1c concentration, and type of anti-diabetic drugs.
Patients with type 2 diabetes and high cardiovascular risk have similar rates of cardiovascular events when treated with alogliptin compared to placebo, according to the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. The findings provide reassurance for clinicians treating patients with type 2 dia...
The RELAX-AHF trial demonstrated serelaxin's efficacy in relieving dyspnea in HFpEF patients, particularly within the first 24 hours. The VIVIDD trial also showed vildagliptin to be non-inferior to placebo in improving LVEF in HFrEF patients with type 2 diabetes.
A study at Henry Ford Hospital found that patients taking GLP-1 medications had a reduced risk of hospitalization for heart failure and fewer deaths. The retrospective study included 4,427 diabetic patients and adjusted for various factors to identify the effect of GLP-1 medication use.
Researchers at Sahlgrenska Academy, University of Gothenburg, have found that metformin is effective in reducing the risk of cardiovascular disease, serious infection, and death in patients with mild kidney impairment. The study suggests that metformin can be prescribed for many more patients with diabetes than previously thought.
A steady job is associated with improved medication adherence and reduced risk of non-adherence among working-age diabetics. Lack of employment increases stress, financial strain, and access barriers, leading to lower adherence rates.
A hormone with anti-diabetic properties called adiponectin has been shown to reduce depressive-like symptoms in stressed mice. Administering adiponectin produced antidepressant-like effects, especially in mice with obesity and type 2 diabetes.
A study found that Medicare beneficiaries with depression who faced a coverage gap in their Part D plan were more likely to discontinue their antidepressants. The study, which analyzed data from over 65,000 patients, also found similar reductions in the use of other essential medications, including heart failure drugs and antidiabetics.
Researchers have discovered that liquorice root contains substances called amorfrutins, which reduce blood sugar levels and are also anti-inflammatory. These natural compounds may be suitable for treating adult diabetes and could lead to the development of new treatments.
A French research team analyzed data from over 13,000 patients to investigate the long-term effects of metformin. The study found no significant impact on mortality or cardiovascular risk with metformin compared to other drugs.
A systematic review of FDA warnings and alerts over 20 years found that communicating health risks can be a complex science, with varying impacts on drug use and health behaviors. The most effective notices were those warning about serious adverse events, but even these had variable effects.
Researchers at Dana-Farber Cancer Institute have developed prototype drugs with powerful anti-diabetic effects without the severe side effects of current medications. The new compounds target PPAR-gamma, a metabolic regulator controlling fat cell development, and block phosphorylation to minimize risk.
Researchers have discovered a new class of anti-diabetic compounds that target a unique molecular switch, potentially offering fewer side effects than existing drugs. The new compound, SR1664, blocks Cdk5's action on PPARG and shows improved blood sugar levels without weight gain or fluid retention.
A circuit in the brain regulating serotonin-receptor signaling may explain anti-diabetic actions independent of body weight and feeding. Reactivating this receptor in specific neurons protects mice from insulin resistance and metabolic problems.
A diet study led by Lund University found that a specific diet high in antioxidants, omega fatty acids, and wholegrain products can improve memory and cognitive function. The diet also significantly reduced blood lipids, blood pressure, and inflammation markers.
Researchers found that compounds targeting PPARγ can improve insulin sensitivity without promoting fat cell growth, offering a new target for anti-diabetic treatments. The study suggests a unified framework for understanding the relationship between fat cell dysfunction and anti-diabetic therapies.
A new study published in Molecular Nutrition and Food Research journal reveals that cashew seed extract can improve the body's response to insulin, potentially treating diabetes. The investigation found that only cashew seed extract significantly stimulated blood sugar absorption by muscle cells.
A second-generation anti-obesity drug has shown promise in reducing body weight in rodents without causing psychiatric side effects. The drug targets peripheral tissues and organs, avoiding significant brain exposure. This finding raises the prospect of reviving CB1 receptor blockade for fighting obesity and related diseases.
Diabetes prevalence is set to double by 2030 in sub-Saharan Africa due to rapid urbanization and lifestyle changes. Implementing national diabetes prevention programs involving multiple sectors is crucial to address this public health issue.
Researchers found that pipe and cigar smoking is associated with decrements in lung function consistent with obstructive lung disease. HRT use also increases the risk of coronary heart disease, even after six years.
A study conducted by the University of Chicago found that obstructive sleep apnea (OSA) significantly worsens glucose control in patients with type 2 diabetes. OSA severity is associated with poorer glycemic control and increased HbA1c levels, which can negate the effects of anti-diabetic medications.
Researchers have identified a leptin-controlled gene that can reverse diabetes in animals and may have similar therapeutic effects in humans. The study found that low levels of leptin can correct insulin resistance and diabetes without causing significant weight loss.
A new study found that resveratrol improves diabetes by targeting the brain, potentially leading to orally-delivered medications. Activating sirtuins in the brain mediates resveratrol's beneficial effects, which could lead to more effective targeted diabetes treatments.
A new study published in the International Journal of Obesity found that biotransformed blueberry juice has strong anti-obesity and anti-diabetic effects. The juice was tested on mice prone to obesity, insulin resistance, diabetes, and hypertension, and showed a significant reduction in food intake and body weight.
Research on Pluronic L-81, a synthetic copolymer, reveals its potential in alleviating obesity-induced insulin resistance and type 2 diabetes. The study found that L-81 significantly corrected body weight and plasma glucose levels in genetically diabetic mice.
A recent study published in the New England Journal of Medicine found that Medicare Part D led to increased pharmacy spending among beneficiaries, particularly those with limited or no prior drug coverage. However, this increase was offset by decreased spending on other medical care services such as hospitalizations and doctor visits.
A new study found that combining rosiglitazone with metformin reverses the negative impact on bone healing caused by rosiglitazone. This beneficial effect was observed in an experimental rat model, where metformin improved bone formation and density compared to rosiglitazone treatment alone.
A major international diabetes study of over 52,000 patients from eight countries found that using biphasic BIAsp 30 insulin resulted in significant clinical improvements and greater patient satisfaction. The study showed a 53% reduction in blood glucose levels below seven percent, with major hypoglycaemia incidents falling by 94%.
A phase I clinical trial found rosiglitazone to be safe and well-tolerated in patients with FSGS, suggesting its potential as a treatment option. The study showed that serum albumin and kidney filtration rates affected the drug's activity, warranting further investigation.
Researchers mapped thousands of positions where PPAR gamma regulates genes in fat cells, potentially leading to new therapies for reducing fat cell numbers or altering function. The findings aim to decrease side effects associated with antidiabetic drugs.
Rosiglitazone, an antidiabetic drug, has been found to prevent hepatic fibrosis due to Schistosoma japonicum infection. PPARgamma ligand is thought to play a key role in this process.
Research suggests that diabetes medications thiazolidinediones may increase the risk of fractures, particularly hip and wrist fractures. The study found a double or tripled risk for patients taking these drugs for 12-18 months, highlighting the need for further confirmation through additional studies and clinical trials.
Chronic kidney disease significantly increases the risk of cardiovascular events in diabetic patients. Pioglitazone has been shown to lower this risk, particularly among those with moderate to severe renal disease. The study found that pioglitazone reduced all-cause death, myocardial infarction, and stroke by one-third.
A study by Arlette Darfeuille-Michaud and colleagues reveals that CEACAM6 expression promotes adherent-invasive E. coli's colonization in intestinal epithelial cells of patients with Crohn's disease, indicating a potential diagnostic marker for the condition. Meanwhile, another study by Andrea Hevener and colleagues shows that macropha...
Researchers found that platelets can promote diabetic complications and contribute to inflammation in heart disease. They discovered a common Type II diabetes drug can dampen platelet inflammatory activity, potentially leading to new treatments for vascular diseases.
Researchers have found that two diabetes medications, thiazolidinediones, can prevent the development of multiple sclerosis in mice and reduce symptoms. The study suggests that these insulin-sensitizing drugs may also be effective in treating other neurologic diseases such as Alzheimer's and Parkinson's.
A study published in the journal Diabetes found that a ginseng berry extract completely normalized blood glucose levels, improved insulin sensitivity, lowered cholesterol levels, and decreased weight in diabetic mice. The extract also reduced appetite and increased activity levels in treated mice, leading to significant weight loss.
Two case reports found that rosiglitazone, a new oral anti-diabetic drug, appeared to be associated with liver damage. In contrast, a large retrospective study on hepatitis C virus showed that infected individuals developed few liver-related illnesses, suggesting they may be at lower risk for progressive liver disease.
A recent study found that nearly half of people with type 2 diabetes stop taking their oral anti-diabetic drugs (OADs), leading to a higher risk of complications such as blindness, amputation, and cardiovascular problems. The study revealed that individuals who discontinued treatment were almost three times more likely to die than thos...